Moncef Slaoui and his colleagues at Medicxi have taken the wraps off a new oncology startupt hat wants to interrupt cancer cell-to-cell communication.
X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.
The biopharmaceutical pipeline is growing at double the rate of the small-molecule market, representing the fastest-growing sector of the industry.
Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.
The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.
Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.
No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.
Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.
Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.
Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.
Terazosin, a decades-old drug for enlarged prostate, appears to improve Parkinson's symptoms, tests in animal models and a large patient database show.